Indivior PLC (NASDAQ:INDV) Receives $34.57 Average PT from Brokerages

Indivior PLC (NASDAQ:INDV) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $34.5714.

INDV has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Piper Sandler reiterated an “overweight” rating and set a $41.00 price target (up from $27.00) on shares of Indivior in a research note on Friday, October 31st. HC Wainwright boosted their price target on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research report on Monday. Craig Hallum reaffirmed a “buy” rating and set a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. Finally, Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday.

Indivior Stock Down 2.2%

NASDAQ INDV opened at $32.88 on Tuesday. Indivior has a 52 week low of $7.62 and a 52 week high of $38.00. The firm has a 50 day moving average of $34.32 and a two-hundred day moving average of $26.43. The stock has a market capitalization of $4.11 billion, a PE ratio of 35.74 and a beta of 0.75.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The business had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. On average, equities research analysts expect that Indivior will post 1.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Mark Stejbach acquired 775 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. The trade was a 4.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara Ryan bought 775 shares of the stock in a transaction dated Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. The trade was a 65.24% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 4,871 shares of company stock valued at $172,385 in the last 90 days.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Oaktree Capital Management LP lifted its position in shares of Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after acquiring an additional 246,776,273 shares during the period. Divisadero Street Capital Management LP raised its holdings in Indivior by 2,372.5% during the third quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock worth $81,072,000 after purchasing an additional 3,226,605 shares during the last quarter. Goldentree Asset Management LP acquired a new position in Indivior during the third quarter worth $42,630,000. Newtyn Management LLC boosted its position in Indivior by 61.1% during the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after purchasing an additional 1,592,982 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after purchasing an additional 1,447,939 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.